220 E Grand Ave
South San Francisco
24 articles with Principia Biopharma
Principia Biopharma Inc. announced the pricing of its underwritten public offering of 7,500,000 shares of its common stock at a price to the public of $28.00 per share.
Principia Biopharma Inc. (Nasdaq: PRNB), a late-stage biopharmaceutical company focused on developing novel therapies for immune mediated diseases, today announced that it has commenced an underwritten public offering of $125 million of its common stock.
Principia Announces Positive Preliminary Data of PRN1008 for Immune Thrombocytopenia in Ongoing Phase 1/2 TrialPreliminary results from trial have been accepted as an oral presentation at upcoming American Society of Hematology Annual Meeting
Principia Biopharma Inc. announced positive preliminary data from an ongoing Phase 1/2 trial of its investigational treatment, PRN1008, in a highly treatment-resistant and refractory patient population with immune thrombocytopenia Further updated data from the trial will be presented at an oral scientific session at the 61st American Society of Hematology Annual Meeting in December
Principia Announces Positive Preliminary Data of PRN1008 from its Ongoing Phase 2 Part B Trial in Pemphigus
Principia Biopharma Inc. announced positive preliminary data from its Phase 2 pemphigus, open-label, trial.
Principia Biopharma Announces Positive Data from Phase 2 Pemphigus Vulgaris Trial at 2019 American Academy of Dermatology Annual Meeting in Late-Breaking Presentation
Principia Biopharma Inc. (Nasdaq: PRNB), a late-stage biopharmaceutical company dedicated to bringing transformative oral therapies to patients with significant unmet medical needs in immunology and oncology, today announced Phase 2 clinical data from the Believe-PV study for PRN1008 as part of the Late-breaking Research: Clinical Trials program at the American Academy of Dermatology (AAD) annual meeting in Washington D.C
PRINCIPIA BIOPHARMA ANNOUNCES THE ACCEPTANCE OF DATA FROM PHASE 2 PEMPHIGUS VULGARIS TRIAL AS A LATE-BREAKING PRESENTATION AT 2019 AMERICAN ACADEMY OF DERMATOLOGY MEETING
Principia Biopharma Inc. (Nasdaq: PRNB), a late-stage biopharmaceutical company dedicated to bringing transformative oral therapies to patients with significant unmet medical needs in immunology and oncology, today announced that an abstract has been accepted for oral presentation at the Late-Breaking Research during the 2019 American Academy of Dermatology annual meeting in Washington, D.C.
11/14/2018Leerink Holdings is the Boston-based parent company of Leerink Partners. Leerink Partners is an investment bank focused on healthcare and life sciences.
South San Francisco-based Principia Biopharma is looking to become a publicly traded company and is aiming for a $86 million initial public offering. The company filed its prospectus with the U.S. Securities and Exchange Commission on Aug. 17.
Principia Biopharma Inc. today announced that dosing has been completed for all participants in a Phase 1 clinical trial of PRN2246, a Bruton’s tyrosine kinase (BTK) inhibitor designed to cross the human blood-brain barrier.
Principia Biopharma Initiates Clinical Trial for PRN1008 in Patients With Immune Thrombocytopenia Purpura
Principia also has an on-going clinical program for PRN1008 in patients with pemphigus, another autoimmune disease, where it has seen a promising efficacy and safety profile to date.
Sanofi will write a check for $40 million upfront.
Principia Biopharma Presents Late-Breaking Interim Phase II Data Of PRN1008 In Pemphigus At European Academy Of Dermatology And Venereology Meeting
Principia Biopharma Announces PRN1008 Receives Orphan Drug Designation From FDA For Treatment Of Pemphigus Vulgaris
ASCO2016: Principia Biopharma Announces Presentation Of Initial Clinical Data On PRN1371 At 2016 American Society Of Clinical Oncology (ASCO) Annual Meeting
Guardant Health Announces Collaboration With Principia Biopharma To Use Guardant360 For Monitoring Patient Response And Tumor Evolution In FGFR Inhibitor Trials
Principia Biopharma Advances BTK Inhibitor Program In Autoimmune Disease And FGFR Inhibitor Program In Oncology
Principia Biopharma Presents Full Phase 1 Clinical Trial Results For PRN1008, A Novel Reversible Covalent BTK Inhibitor, Supporting Further Clinical Development In Autoimmune And Inflammatory Diseases
Principia Biopharma And University of California, San Francisco (UCSF) Scientists Announce Publication Of Seminal Paper On Reversible Covalent Drugs In Nature Chemical Biology
Principia Biopharma Appoints Roy Hardiman As Chief Business Officer And Lewis Shuster To Board Of Directors